ABSTRACT
The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.
Subject(s)
Adalimumab/adverse effects , Anti-Inflammatory Agents/adverse effects , Guillain-Barre Syndrome/chemically induced , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Humans , Male , Middle Aged , Psoriasis/complications , Treatment OutcomeABSTRACT
Abstract The use of TNF-α inhibitors for the treatment of moderate to severe psoriasis and psoriatic arthritis is increasingly more frequent. The authors report a case of Guillain-Barré syndrome as a late manifestation of the treatment with adalimumab. Although unusual, this is relevant for professionals who prescribe biologic drugs. We also stress the importance of investigating the past and family medical history regarding demyelinating diseases before starting treatment.